Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

The current state of radiotherapeutics is “the isotope wars”, according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.

Purpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sites Novartis RLT portfolio advancing with new ...

Swiss pharma giant Novartis on Friday revealed plans to build its fourth US radioligand therapy (RLT) manufacturing facility ...

Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...

Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis’ ...

VANCOUVER--(BUSINESS WIRE)--Borealis Biosciences, a next-generation RNA medicines company, today emerged from stealth with $150 million in combined Series A financing from founding investor Versant ...

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT manuf ...

Novartis to build its fourth US radioligand therapy manufacturing facility in Winter Park, Florida with an investment of $23 billion: Basel Monday, January 12, 2026, 10:00 Hrs [IS ...